A study on pharmacovigilance case processing

Anil Kumar Y; Divya A; Sayamma B; Karishma Sk; Ravi Kumar Konda; Santhosh Kumar Ch

doi:10.37022/jiaps.v7i2.338

Y. Anil Kumar Dept. of Pharmaceutical Sciences, Hindu college of Pharmacy, Amaravathi road, Guntur - 522002, Andhra Pradesh, India
A. Divya Dept. of Pharmaceutical Sciences, Hindu college of Pharmacy, Amaravathi road, Guntur - 522002, Andhra Pradesh, India
B. Sayamma Dept. of Pharmaceutical Sciences, Hindu college of Pharmacy, Amaravathi road, Guntur - 522002, Andhra Pradesh, India
Sk. Karishma Dept. of Pharmaceutical Sciences, Hindu college of Pharmacy, Amaravathi road, Guntur - 522002, Andhra Pradesh, India
Konda Ravi Kumar Dept. of Pharmaceutical Sciences, Hindu college of Pharmacy, Amaravathi road, Guntur - 522002, Andhra Pradesh, India
Ch. Santhosh Kumar Dept. of Pharmaceutical Sciences, Hindu college of Pharmacy, Amaravathi road, Guntur - 522002, Andhra Pradesh, India

DOI https://doi.org/10.37022/jiaps.v7i2.338

Abstract

Pharmacovigilance plays an vital role in modern technology which helps in monitoring and assessing the high-quality of Drugs, detection and stopping of any unfavorable outcomes of drugs. Pharmacovigilance starts with case processing: this involve safety data collection and coding, case management reporting and submission. In case of clinical trial, it is the investigator or in case of post-marketing trial, it is either the physician or the prescriber or the patient himself who reports the adverse event or any drug-related problem. Pharmacovigilance case processing helps to get clear information regarding the drug and outcomes by using various software technologies. Arugs database, cemflow, vigibase and ICSR are few software used nowadays. Case processing helps to monitor and track all serious adverse events, and medically significant ADRs and other medical related product information followed by timely processing and reporting of such information according with company and regulatory reporting.

Keywords: Pharmacovigilance, high-quality of Drugs

Downloads

Download data is not yet available.

References

1. Pharmacovigilance available at: https://www.researchgate.net/publication/345332852_Introduction_and_
evaluation_of_pharmacovigilance_for_beginners/link/5fa41982a6fdcc0624153665/download.
2. Aronson JK. Louis Lewin-Meyler’s predecessor edi 1. Side Effects of Drugs Annual Vol 27, Elsevier. 2004. 2. Hamburg MA. Innovation, regulation, and the FDA. N Engl J Med. 2010;363(25):2228-32.
3. Van Grootheest K, Dukes G. Leopold Meyler (1903- 1973): a pioneer in the study of adverse effects of drugs. Int J Risk Saf Med. 2003/2004;16:67-70.
4. M. Rupesh Kumar, Surendra Bodhanapu , T. Tamizh Mani, P. Phaneendra and O.M. Fasalu Rahiman, Pharmacovigilance and importance in drug regulations: an overview, Article in Der Pharmacia Lettre · March 2011: 165
5. The importance of pharmacovigilance-safety monitoring of medicinal products. Geneva: World Health Organization; 2002. Available at: https://apps.who.int/medicinedocs/pdf/s4893e/s4893 e.pdf. Accessed on 01 July 2020
7. Pushpraj P. Gawai, Introduction and evaluation of pharmacovigilance for beginners ,International Journal of Scientific Reports , October 2020, Vol 6, Issue 10: 427-428.
8. Ritesh Bhangale, Sayali Vaity and Niranjan Kulkarni, A day in the life of a pharmacovigilance case processor, perspect clin res.207 oct-dec; 8(4): 192-195.
9. Protocol for National Pharmacovigilance Program, CDSCO, Ministry of Health and Family Welfare, Government of India, November 2004.
10. N.J. White, Proceedings of the XXVIIth CIOMS Conference, Geneva, Switzerland 14-15 Sep. 1993, Z. Bankowski, J.F. Dunne (eds) CIOMS, Geneva 1994, 126 –135.
11. Managing the Risks from Medical Product Use: Creating a Risk Management Framework. http://www.fda.gov/oc/tfrm/1999report.html.
12. Surveillance of adverse events following immunization, Field guide for managers of immunization programmes, Geneva, WHO, 1997.
13. The Safety of Medicines in Public Health Programmes: Pharmacovigilance an essential tool. WHO, 2006. Available at: https://www.who. int/medicines/areas/quality_safety/safety_efficacy/Ph armacovigilance_B.pdf?ua=1. Accessed on 01 July 2020.
14. Guideline for post marketing reporting of adverse drug experiences. Available at: https://www.fda. gov/media/83280/download. Accessed on 01 July 2020.
15. Konda Ravi Kumar et al., A Review On Prophylaxis And Treatment Of Migraine, World Journal of Pharmacy and Pharmaceutical Sciences, Volume 5, Issue 8, 451-455,2016.
16. Neelima, D., B. Shivani, M. Kranthi, M. Kranthi, B. Praveena, and K. R. Kumar. “A CASE STUDY ON WEILS DISEASE”. World Journal of Current Medical and Pharmaceutical Research, Vol. 1, no. 5, Oct. 2019, pp. 164-5, https://www.wjcmpr.com/index.php/journal/article/view/34.
17. Y, A. K., S. K, L. L., Konda, R. K., & A, P. (2021). A review study on the anti depressant and anti oxidant activities of pisidum guajava and allium sativum. Journal of Innovations in Applied Pharmaceutical Science (JIAPS), 6(3), 27-30. https://doi.org/10.37022/jiaps.v6i3.237.
18. Dr. Konda Ravi Kumar et al, Study of Health Related Quality Of Life in Patients with Gastro esophageal Reflux Disease, IOSR Journal of Pharmacy and Biological Sciences, 13, 4, 70-75, 2018.